NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60505-6095-00 | 60505-6095 | Bendamustine Hydrochloride | Bendamustine Hydrochloride | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | June 19, 2023 | In Use | |
60505-6068-00 | 60505-6068 | Pemetrexed disodium | Pemetrexed | 750.0 mg/30mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
60505-6067-00 | 60505-6067 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
60505-6066-00 | 60505-6066 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
60505-6065-00 | 60505-6065 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
60505-6050-04 | 60505-6050 | Bortezomib | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
60505-4764-06 | 60505-4764 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | July 16, 2021 | In Use | |
60505-4631-03 | 60505-4631 | Cyclosporine | CycloSPORINE, Modfied | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov. 5, 2019 | Aug. 31, 2023 | In Use |
60505-4630-03 | 60505-4630 | Cyclosporine | CycloSPORINE, Modfied | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov. 5, 2019 | Aug. 31, 2023 | In Use |
60505-4537-02 | 60505-4537 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
60505-4537-01 | 60505-4537 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | March 8, 2023 | In Use |
60505-4536-02 | 60505-4536 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 9, 2023 | In Use | |
60505-4535-02 | 60505-4535 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
60505-4535-01 | 60505-4535 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | March 8, 2023 | In Use |
60505-4534-02 | 60505-4534 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
60505-4534-01 | 60505-4534 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | March 8, 2023 | In Use |
60505-4533-02 | 60505-4533 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
60505-4533-01 | 60505-4533 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | March 8, 2023 | In Use |
60505-4532-02 | 60505-4532 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 9, 2023 | In Use | |
60505-4512-03 | 60505-4512 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug. 8, 2023 | In Use | |
60505-4327-03 | 60505-4327 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Nov. 23, 2018 | Aug. 11, 2021 | In Use |
60505-4327-01 | 60505-4327 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Nov. 23, 2018 | In Use | |
60505-3877-09 | 60505-3877 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 25, 2015 | Jan. 31, 2021 | No Longer Used |
60505-3877-03 | 60505-3877 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 25, 2015 | Jan. 31, 2021 | No Longer Used |
60505-3255-08 | 60505-3255 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | May 31, 2019 | No Longer Used | |
60505-3255-03 | 60505-3255 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | Dec. 31, 2021 | No Longer Used | |
60505-3255-01 | 60505-3255 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | May 31, 2019 | No Longer Used | |
60505-3036-07 | 60505-3036 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3036-03 | 60505-3036 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3036-01 | 60505-3036 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-07 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-06 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-05 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-03 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-2985-03 | 60505-2985 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | March 1, 2021 | No Longer Used | |
60505-2901-09 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-05 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-03 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-01 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-00 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-09 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-08 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-03 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-01 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-00 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2710-08 | 60505-2710 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 27, 2008 | Dec. 1, 2008 | No Longer Used | |
60505-2710-02 | 60505-2710 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 27, 2008 | Dec. 1, 2008 | No Longer Used | |
60505-2710-00 | 60505-2710 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 27, 2008 | Dec. 1, 2008 | No Longer Used | |
60505-2642-03 | 60505-2642 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use | |
60505-2642-01 | 60505-2642 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | In Use |
Found 10,000 results in 9 milliseconds — Export these results